Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma - Quiz - MDSpire

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • By

  • Rakesh Popat

  • Bradley Augustson

  • Mercedes Gironella

  • Cindy Lee

  • Paul Cannell

  • Nashita Patel

  • Ravi S. Kasinathan

  • Rachel Rogers

  • Mehreen Shaikh

  • Amy Curry

  • Fernando Carreño

  • Sumita Roy-Ghanta

  • Joanna Opalinska

  • Hang Quach

  • October 21, 2024

  • 0 min

Share

Original Source(s)

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • by Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach

  • October 21, 2024

Related Content

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma